AzTrials
AzTrials

CataractMMAQ-IOLNCT07740590

Visual Adaptation and Quality of Life After Different IOL Implantation Strategies

An observational study of Cataract and Aphakia - Lens Capsule Present, run by Sichuan Academy of Medical Sciences at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This longitudinal observational study aims to evaluate long-term visual adaptation trajectories, optical quality, and patient-reported outcomes in age-related cataract patients following bilateral implantation of multifocal or mix-and-match intraocular lenses (IOLs). Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Cataract, Aphakia - Lens Capsule Present
What is being tested?
Bilateral Bifocal IOL Implantation, Bifocal and EDOF IOL Mix-and-Match Implantation and Bifocal and Monofocal IOL Mix-and-Match Implantation
Type of treatment
Medical device
How many people
264 participants
Where
1 siteChina
Study dates
1 Mar 2025to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients diagnosed with age-related cataracts who underwent phacoemulsification and intraocular lens (IOL) implantation

Who may be able to join

  • Age 18 years or older with age-related cataract requiring bilateral phacoemulsification and intraocular lens (IOL) implantation
  • Corneal astigmatism less than 0.75 D
  • Good general health and willing to complete all postoperative follow-up visits
  • Signed written informed consent

Who cannot join

  • Previous ocular surgery or ocular trauma
  • Coexisting ocular diseases affecting visual potential, such as corneal opacity, glaucoma, macular degeneration, or diabetic retinopathy
  • Intraoperative or postoperative complications (e.g., posterior capsule rupture)
  • Systemic diseases that may interfere with visual outcomes or follow-up compliance

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Xiangjun Fu, Ph.D. contact

+86-28-87393999

243981469@qq.com

China1 site, 1 recruiting
  • Sichuan Provincial People's Hospital

    Chengdu

    Xiang Yang,, M.D, +86-28-87393999, xiangyangttt@126.com

    Recruiting

Other trials in China

About this study

Official title: Evaluation of Visual Adaptation and Optical Performance in Patients With Bilateral Multifocal or Mix-and-Match Intraocular Lens Implantation: A Longitudinal Observational Study

This longitudinal observational study aims to evaluate long-term visual adaptation trajectories, optical quality, and patient-reported outcomes in age-related cataract patients following bilateral implantation of multifocal or mix-and-match intraocular lenses (IOLs). Patients will be followed up longitudinally after surgery to systematically assess visual performance and quality of life.

Read the detailed description

Multifocal and mix-and-match intraocular lens (IOL) implantation strategies have been widely adopted to restore full-range vision after cataract surgery. However, patients often experience varying rates and trajectories of neuroadaptation to optical phenomena such as glare and halos.

This study prospectively observational tracks age-related cataract patients undergoing bilateral IOL implantation (homogeneous or mix-and-match combinations). Postoperative evaluations are systematically conducted across key follow-up time points (ranging from 1 week up to 6 months postoperatively). Primary evaluations involve standard ophthalmological measurements alongside validated visual questionnaires (including the MMAQ) to capture longitudinal adaptation patterns, spectacle independence, and overall visual satisfaction.

Being tested
Bilateral Bifocal IOL Implantation, Bifocal and EDOF IOL Mix-and-Match Implantation, Bifocal and Monofocal IOL Mix-and-Match Implantation
Keywords
Intraocular Lenses, Multifocal Intraocular Lenses, Neuroadaptation, Visual Performance, Quality of Life
Medical subject headings
Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bilateral Bifocal IOL ImplantationDevice

    Bilateral phacoemulsification with bifocal intraocular lens implantation in both eyes.

  • Bifocal and EDOF IOL Mix-and-Match ImplantationDevice

    Bilateral phacoemulsification with bifocal intraocular lens implantation in one eye and EDOF intraocular lens implantation in the contralateral eye.

  • Bifocal and Monofocal IOL Mix-and-Match ImplantationDevice

    Bilateral phacoemulsification with bifocal intraocular lens implantation in one eye and monofocal intraocular lens implantation in the contralateral eye.

Study groups in NCT07740590
Study groupRoleWhat they receive
Dual focus + Dual focus groupPatients undergoing bilateral implantation of dual-focus intraocular lenses in both eyes
Receives: Device: Bilateral Bifocal IOL Implantation
Dual focus + EDOF groupPatients undergoing bilateral implantation of a dual-focus intraocular lens in one eye and an Extended Depth of Focus (EDOF) lens in the contralateral eye
Receives: Device: Bifocal and EDOF IOL Mix-and-Match Implantation
Dual focus + Single focus groupPatients undergoing bilateral implantation of a dual-focus intraocular lens in one eye and a monofocal intraocular lens in the contralateral eye.
Receives: Device: Bifocal and Monofocal IOL Mix-and-Match Implantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Subjective Visual Adaptation Score (Multifocal Motor Adaptation Questionnaire, MMAQ)

    Assessed using the Multifocal Motor Adaptation Questionnaire (MMAQ), a custom-designed questionnaire developed by the research team to measure subjective visual adaptation and symptoms in patients following intraocular lens implantation. Scores range from 0 to 100, with higher scores indicating higher levels of visual adaptation and satisfaction.

    Measured: Preoperatively, and postoperatively at 1 week, 1 month, 3 months, and 6 months

Secondary outcomes (10)
  1. Total High-Order Aberrations (HOAs)

    Change in total high-order aberrations (3rd to 6th order RMS, measured in micrometers) from baseline to 1 month, 3 months, and 6 months postoperatively, evaluated using an ocular/corneal wavefront aberrometer under a standardized pupil diameter (e.g., 4.0 mm / 6.0 mm).

    Measured: Postoperatively at 1 month, 3 months, and 6 months

  2. Defocus Curve

    Visual acuity evaluated at varying lens powers ranging from +1.50 D to -4.00 D in 0.50 D steps to assess the range of clear vision

    Measured: Postoperatively at 1 month, 3 months, and 6 months

  3. Uncorrected Binocular Distance Visual Acuity (UDBVA)

    Change in uncorrected binocular distance visual acuity measured at 4 meters under photopic lighting conditions using standard Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts. Lower LogMAR values indicate superior visual acuity.

    Measured: Preoperatively, and postoperatively at ,1 month, 3 months, and 6 months

  4. Spherical Aberration

    Change in spherical aberration ( Zernike coefficient, measured in micrometers) from baseline to 1 month, 3 months, and 6 months postoperatively, evaluated using an ocular/corneal wavefront aberrometer under a standardized pupil diameter (e.g., 4.0 mm / 6.0 mm).

    Measured: Postoperative 1 month, 3 months, and 6 months

  5. Horizontal Coma

    Change in horizontal coma ( Zernike coefficient, measured in micrometers) from baseline to 1 month, 3 months, and 6 months postoperatively, evaluated using an ocular/corneal wavefront aberrometer under a standardized pupil diameter (e.g., 4.0 mm / 6.0 mm).

    Measured: Postoperative 1 month, 3 months, and 6 months

  6. Vertical Coma

    Change in vertical coma Zernike coefficient, measured in micrometers) from baseline to 1 month, 3 months, and 6 months postoperatively, evaluated using an ocular/corneal wavefront aberrometer under a standardized pupil diameter (e.g., 4.0 mm / 6.0 mm).

    Measured: Postoperative 1 month, 3 months, and 6 months

  7. Total Coma RMS

    Change in total coma measured in micrometers) from baseline to 1 month, 3 months, and 6 months postoperatively, evaluated using an ocular/corneal wavefront aberrometer under a standardized pupil diameter (e.g., 4.0 mm / 6.0 mm).

    Measured: Postoperative 1 month, 3 months, and 6 months

  8. Uncorrected Binocular Intermediate Visual Acuity (UIBVA)

    Change in uncorrected binocular intermediate visual acuity measured at 80 cm (and/or 66 cm) under photopic lighting conditions using standard Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts. Lower LogMAR values indicate superior visual acuity.

    Measured: Preoperatively, and postoperatively at 1 month, 3 months, and 6 months

  9. Uncorrected Bincorrected Near Visual Acuity (UNBVA)

    Change in uncorrected binocular near visual acuity measured at 40 cm under photopic lighting conditions ($85\ \text{cd/m}^2$) using standard Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts. Lower LogMAR values indicate superior visual acuity.

    Measured: Preoperatively, and postoperatively at 1 month, 3 months, and 6 months

  10. Contrast Sensitivity

    Change in contrast sensitivity (logarithmic values) across standardized spatial frequencies (1.5, 3, 6, 12, and 18 cycles per degree) from baseline to 1 month, 3 months, and 6 months postoperatively. Evaluated using a standardized contrast sensitivity chart (e.g., CSV-1000 or Optec 6500) under both photopic and mesopic lighting conditions (with and without glare).

    Measured: Postoperative 1 month, 3 months, and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2026
  2. Study start1 Mar 2025
  3. Primary completion31 Oct 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
264 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07740590
Sponsor's protocol ID
SCCHEC-2024-425
Acronym
MMAQ-IOL
Status last verified
Jul 2026
First submitted
21 Jul 2026
Last updated
31 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Cataract and Aphakia - Lens Capsule Present, run by Sichuan Academy of Medical Sciences at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xiangjun Fu, Ph.D. (+86-28-87393999, 243981469@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Subjective Visual Adaptation Score (Multifocal Motor Adaptation Questionnaire, MMAQ) (time frame: Preoperatively, and postoperatively at 1 week, 1 month, 3 months, and 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
MMAQ-IOL Clinical Trial NCT07740590 | AzTrials